



The following message was sent to you through the Alaska Public Health Alert Network (AK PHAN). Please share this information with others who may be interested. Note: Contact information for the Alaska Section of Epidemiology can be found at the end of this message.

Updated Recommendations for the Use of Respiratory Syncytial Virus Vaccine in Pregnancy and Nirsevimab for Infants during the 2024–25 Season

March 6, 2025

Summary

Given the ongoing circulation of respiratory syncytial virus (RSV) in Alaska this year, the Alaska Section of Epidemiology (SOE) recommends that Alaska clinicians continue to administer RSVpreF (Pfizer, Abrysvo) vaccination during weeks 32–36 of pregnancy through March 31, 2025. SOE also recommends Alaska clinicians administer nirsevimab for eligible infants through May 31, 2025.

Background

- RSVpreF Vaccine
 - The Advisory Committee on Immunization Practices (ACIP) recommends a single lifetime dose of Abrysvo maternal RSV vaccine during weeks 32 through 36 of pregnancy, seasonally administered from September through January 31, to reduce the chance of severe RSV in infants.
 - RSV activity remains high in Alaska, as noted in the [AK Respiratory Virus Snapshot](#).
- Nirsevimab
 - Nirsevimab is a monoclonal antibody that offers passive immunity against RSV in infants, protecting them from severe RSV-related illness.
 - ACIP recommends routine administration of nirsevimab for infants during their first RSV season and for select high-risk children during their second RSV season, from October 1 through March 31.
- ACIP acknowledges that jurisdictions like Alaska, with unique RSV circulation patterns, may adopt locally tailored recommendations for RSVpreF and nirsevimab.

Updated Recommendation for RSVpreF Vaccine and for Nirsevimab this Season

- Due to ongoing RSV circulation in Alaska, SOE recommends that clinicians continue to offer RSVpreF vaccination during 32–36 weeks of pregnancy through March 31, 2025, and to offer nirsevimab to eligible infants through May 31, 2025.
- If RSV continues to circulate at elevated levels, further extensions may be considered.

Resources

- Alaska SOE RSV Immunization Guidance for the 2024-25 Season: https://epi.alaska.gov/bulletins/docs/b2024_10.pdf
- Alaska SOE RSVPreF *Bulletin*: https://epi.alaska.gov/bulletins/docs/b2023_17.pdf
- Alaska Respiratory Virus Snapshot: <https://health.alaska.gov/dph/Epi/id/Pages/COVID-19/covidandflu.aspx>
- Alaska SOE RSV Webpage: <https://health.alaska.gov/dph/Epi/id/Pages/dod/rsv/default.aspx>
- CDC: [ACIP Evidence to Recommendations for Use of Pfizer RSVpreF in Pregnant Women](#)
- CDC: [Clinical Guidance for RSV Immunizations and Vaccines](#)